Table 1.
Patient Demographics, Injury Status, and Procedure Characteristics of the Nonanticoagulated and Anticoagulated Cohorts.
| Nonanticoagulated (n = 367) | Anticoagulated (n = 112) | P Value | |
|---|---|---|---|
| Age, mean (SD), years | 81.7 (9.9) | 83.8 (7.7) | .022 |
| CCI, mean (SD) | 1.2 (1.6) | 1.8 (1.3) | <.001 |
| Fracture type | |||
| Intertrochanteric, n (%) | 181 (49.3%) | 52 (46.4%) | .623 |
| Femoral neck, n (%) | 168 (45.8%) | 52 (46.4%) | |
| Subtrochanteric n (%) | 18 (4.9%) | 8 (7.1%) | |
| Procedure performed | |||
| CPPP, n (%) | 36 (9.8%) | 15 (13.4%) | .779 |
| SHS, n (%) | 37 (10.1%) | 9 (8.9%) | |
| Cephalomedullary nail, n (%) | 176 (48.0%) | 55 (49.1%) | |
| Hemiarthroplasty, n (%) | 85 (23.2%) | 23 (20.5%) | |
| Total hip arthroplasty, n (%) | 32 (8.7%) | 8 (7.1%) | |
| Plate and screws, n (%) | 1 (0.3%) | 1 (0.9%) | |
| Anesthesia choice | |||
| General, n (%) | 226 (61.6%) | 94 (83.9%) | <.001 |
| Spinal, n (%) | 141 (38.4%) | 18 (16.1%) | |
| Anticoagulant | |||
| Warfarin, n (%) | 37 (33.0%) | ||
| Clopidogrel, n (%) | 36 (32.1%) | ||
| Factor Xa inhibitors, n (%) | 24 (21.4%) | ||
| Dabigatran, n (%) | 4 (3.6%) | ||
| Aspirin, n (%) | 10 (8.9%) | ||
| Dipyridamole/aspirin, n (%) | 1 (0.9%) |
Abbreviations: CCI, Charlson comorbidity index; CRPP, closed reduction percutaneous pinning; SD, standard deviation; SHS, sliding hip screw.